Saturday, November 21, 2026 · Off-Session
Independent Political Coverage
HomeLawmakersBillsElectionsLegislatureGovernorCommentaryArchive

Mike Crapo Seeks Review of Kratom Scheduling Changes

U.S. Sen. Mike Crapo of Idaho joined seven other Republican senators in asking the Drug Enforcement Administration and Food and Drug Administration to explain and reconsider proposed emergency scheduling changes involving semi-synthetic substances derived from kratom.

The senators questioned a revised federal proposal that would permit higher levels of 7-hydroxymitragynine, known as 7-OH, and MP in over-the-counter kratom products than occur naturally in kratom. Crapo has represented Idaho in the Senate since 1999 and is chairman of the Senate Finance Committee.

Federal proposal changed

In July, the DEA proposed placing 7-OH above a 0.05 percent threshold in Schedule I. The agency later scheduled three semi-synthetic kratom-related substances, including MP, under Schedule I.

In October, the DEA revised the proposal by doubling the initial 7-OH threshold and removing MP from Schedule I. The senators asked the agencies for the scientific and medical evaluations used to support the higher threshold.

The letter also seeks an explanation of how the revised standard would better protect families. It calls for the DEA to reconsider the 7-OH threshold and to place kratom substances containing any amount of MP in Schedule I.

Idaho health concerns

Kratom leaves contain mitragynine and 7-hydroxymitragynine, compounds that can be concentrated and chemically altered into MP, MGM-15 and MGM-16. Kratom and related products are sold over the counter nationwide.

The FDA lists liver toxicity, seizures, substance use disorder and, in rare cases, death among potential kratom side effects. Idaho’s Department of Health and Welfare reported 83 kratom-related overdose deaths between 2020 and 2024.

Bonneville County reported six deaths over 18 months in a November 2025 report. State health authorities linked 7-OH products and concentrated extracts with dependence, addiction, acute psychosis, slowed breathing, cardiac arrest and death.

The lawmakers said the combined 7-OH and MP threshold proposed by the DEA is “inappropriately high and unsound.” They also said consumers deserve confidence that products sold on store shelves are subject to sound public-health decisions.

Other signers were Sens. Chuck Grassley, Jim Risch, Susan Collins, Rick Scott, Bill Cassidy, Jerry Moran and Shelley Moore Capito.